Avastin for Post-photocoagulation Macular Edema

Phase 4

Withdrawn

• Conditions: Macular Edema
• Interventions: Drug: Bevacizumab; Procedure: Panretinal Photocoagulation

• Registration Number: NCT00801866
• Lead Sponsor: Asociación para Evitar la Ceguera en México

Brief Summary

to evaluate the efficacy of a single intravitreal bevacizumab (IVB) injection, 0.1mL (2.5mg), against panretinal photocoagulation (PRP)-induced macular thickening and visual disturbance in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) and good vision

Detailed Description

Not available

Study Timeline

• Study Start: 2008-12
• Primary Completion: 2008-12
• Study Completion: 2008-12
• Study First Submitted: 2008-12-03
• Study First Submitted QC: 2008-12-03
• Study First Posted: 2008-12-04
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-29
• Last Update Posted: 2024-05-30

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patients with Proliferative retinopathy or severe non-proliferative retinopathy
• BCVA of 20/63 or better (56 ETDRS letters
• No history of Macular Edema
• Central Retinal Thickness of 250mics or more

Exclusion Criteria

• Previous treatment.
• Other ophthalmic diseases. history of Nephropathy, heart diseases and pregnancy
• Media opacities

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group 1	Bevacizumab	Panretinal Photocoagulation + Bevacizumab
Group 2	Panretinal Photocoagulation	Panretinal Photocoagulation

Primary Outcome Measures

Name	Time	Method
Best Corrected Visual Acuity

Secondary Outcome Measures

Name	Time	Method
Central Retinal Thickness.

Trial Locations

Locations (1)

Asociación para Evitar la Ceguera en México; 🇲🇽 Mexico, DF, Mexico